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1. Introduction 
Glycaemia is a homeostatic parameter that is very efficiently controlled thanks to the 
equilibrium that exists between the mechanisms involved in supply and removal of blood 
glucose (Fig. 1). 
 
 
Fig. 1. Control of glycaemia. Plasma glucose concentration is closely controlled thanks to 
equilibrium between the mechanisms that supply glucose to the blood and remove it. 
The intestinal absorption is one of the mechanisms that supplies glucose to the blood and 
occurs in two steps (Fig. 2): the first is mediated by the Na+-glucose transporter (SGLT1) 
glycolysis,
    Enter to cells 
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located at the apical membrane of the enterocyte and it translates 2 Na+ ions in favour of its 
concentration gradient per molecule of glucose moved in favour or against its concentration 
gradient into the cell, depending on the amount of the carbohydrate ingested and the time 
of digestion. The second step is carried out by the glucose transporter 2 (GLUT2) situated at 
the basolateral membrane of the enterocyte and this is able to transport glucose by a 
facilitated diffusion in or out of the cell (Nelson & Cox, 2005). 
During a short fasting period, hepatic glycogen is degraded (glycogenolysis) in order to 
supply glucose to the blood. If the fasting period is prolonged a new synthesis of glucose 
occurs (gluconeogenesis) especially in liver and kidney. The final product of both processes 
is glucose-6-phosphate which is hydrolyzed to glucose and phosphate by the enzyme 
glucose-6-phosphatase (EC 3.1.3.9), allowing the glucose to exit the cell and enter the blood. 
In consequence this enzyme plays an important role in controlling the glycaemia (Ashmor 
and Weber 1959). The glucose-6-phosphatase is located in the endoplasmic reticulum (80-90 
%) and nuclear envelope (10-20 %) mainly in the liver, kidney, enterocyte and ǃ cells of 
pancreatic islets. Based on kinetic, genetic and molecular studies, Arion et al., (1975) and 
Burchell & Waddell (1991) postulated that the glucose-6-phosphatase is constituted by (Fig. 
3): A transmembrane protein, the catalytic subunit, whose active centre faces the cistern of 
the endoplasmic reticulum and shows a low specificity, being able to hydrolyze several 
phosphoric esters and pyrophosphate. 
 
 
Fig. 2. Glucose intestinal absorption. It is a process that occurs in two steps, the first is 
mediated by SGLT1, which transports one molecule of glucose and 2 Na+ and is located at 
the apical membrane of the enterocyte. The second is carried out by the GLUT2 which 
transports glucose in favour of it gradient and is placed at the basolateral membrane of the 
cell. The participation of the Na+-K+ ATPase located on the basolateral membrane is also 
required to maintain the ionic gradients. 
T1 is a highly specific transporter for glucose-6-phosphate, the substrate of the enzyme. The T2 
is able to transport phosphate, pyrophosphate and carbamoylphosphate, and it has been 
suggested that comprises by 2 subunits. The glucose produced by the enzyme is transported 
by T3 also called GLUT 7. Finally it is thought there exists a stabilizing protein for the catalytic 
subunit. The glucose-6-phosphatase in addition to its hydrolytic activity, in conditions of high 
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glucose concentration and a phosphate donor such as pyrophosphate or carbamoylphosphate 
is able to synthesize glucose-6-phosphate (Foster &  Nordlie, 2002). 
 
 
1. Glucose-6-phosphate + H2O ---------------------------- glucose + phosphate 
2. Mannose-6-phosphate + H2O ------------------------ mannose + phosphate 
3. Pyrophosphate + H2O ----------------------------------------------- 2 phosphates 
4. Glucose + pyrophosphate --------------- glucose6-phosphate + phosphate 
5. Glucose + carbamoylphosphate ----- glucose-6-phosphate + NH3 + CO2 
Fig. 3. Glucose-6-phosphatase model. Arion et al., (1975) and Burchell & Waddell (1991) 
postulated the model of the catalytic subunit and transporters for the microsomal glucose-6-
phosphatase. G-6-Pase: catalytic subunit; S.P: stabilizing protein; PPi: pyrophosphate; Pi: 
phosphate and E.R: endoplasmic reticulum. The glucose-6-phosphatase catalytic subunit is 
able to catalyze reactions 1-5. 
The glucose transporters, GLUTs, (Joost & Thorens, 2001) mediate the facilitated transport of 
the glucose in and out of the different cells; of particular interest is the participation of the 
GLUT 4 which is located in skeletal  and hart muscle and adipose tissue. The GLUT 4 is held 
in intracellular vesicles and by insulin action is translated to the plasma membrane and in 
consequence entry of glucose into those tissues increases thus lowering the glycaemia. 
Drugs that inhibit the mechanism supplying glucose to the blood are considered 
antihyperglycaemic agents, on the other hand those that increase, directly or indirectly, the 
glucose entry to the tissues are considered hypoglycaemic agents. McCormack et al., (2001) 
suggest that the enzyme glucose-6-phosphatase could be a potential target for 
antihyperglycaemic agents. 
The microsomal fraction, which is enriched in endoplasmic reticulum, obtained by 
differential centrifugation is composed of intact and disrupted vesicles; the proportions of 
each can be measured assaying the glucose-6-phosphatase using mannose-6-phosphate as 
substrate, a molecule that is not translated by the T1 transporter (Arion et al., 1976) in 
consequence all the mannose-6-phosphate hydrolyzed, by the microsomal fraction, is due to 
the activity of the catalytic subunit of the disrupted vesicles. The microsomal fraction 
Cytosol 
Cistern 
G-6-P 
G-6-P 
+ Glucose
S.P.
G-6-Pase
T1 T2
B A 
Glucose
T3
E.R. 
Membrane 
PPi
PPi
Pi
Pi
www.intechopen.com
 
Phytochemicals – Bioactivities and Impact on Health 
 
336 
prepared without further treatment is called non-treated; the microsomes can be disrupted 
by the use of detergents, nitrogen cavitation, sonic disruption and more recently by the use 
of histones (Benedetti et al., 2002). The term intact microsome is theoretical, and is estimated 
by subtracting from the enzyme activity of the non-treated microsomes that of the enzyme 
exhibited by the disrupted vesicles present in such preparations. Latency is a common 
characteristic of membranes bound enzymes, corresponding to the activity expressed only 
when the membrane are disrupted and is not present in the non-treated system. Generally it 
is calculated as the percentage of increase in activity due to the disruption of the vesicles. 
Since time immemorial humans have been using plants for the empirical treatment of different 
illnesses, and in particular diabetes. In Venezuela, like many other tropical countries, the 
leaves of the Bauhinia species have been used by folk medicine in the empirical treatment of 
diabetes. The plants, belonging to the Fabaeceae family (Hoyos 1978) are trees that can reach 10 
m in height, with large well-developed evergreen leaves divided from the apex to 1/3 of its 
length and are hermaphrodite. The specie Bauhinia megalandra is characterized by having white 
flowers either single or in raceme with long and thin petals; the fruit is brown located in a 
compact pod. It is fast growing, long-lived and with deep roots (Figure 4).  
The Bauhinia megalandra used on this work was always collected during the rainy season in the 
campus of the Universidad Central de Venezuela at Caracas and identified by Dr. Stefen Tillett 
of the Ovalles Herbarium of the Pharmacy Faculty of the Universidad Central de Venezuela.  
2. Effects of Bauhinia megalandra leaf aqueous extract on gluconeogenesis 
and glucose-6-phosphatase 
Due to good results reported for metabolic studies using precision-cut liver slices (McKee et 
al., 1988; Dogterom, 1993), we studied the gluconeogenesis capacity of 200 μm thick liver 
slices prepared from 48 h fasted rats using a Krundieck Tissue Slicer (Alabama Research and 
Development, Alabama, USA), and incubated as described elsewhere (Krebs et al., 1963), in 
Krebs-Ringer bicarbonate buffer supplemented with bovine serum albumin saturated with 
oleic acid and using lactate or fructose as gluconeogenic substrate (Gonzalez-Mujica et al., 
1998) in the absence (control) or presence an aqueous extract of Bauhinia megalandra leaves. 
As shown in Table 1, the gluconeogenic activity of the control liver slices was almost linear 
during 90 minutes and of the same magnitude with both substrates.  
In the presence of the plant extract there was a drastic decrease in the gluconeogenic 
capacity of the liver slices, this being of higher magnitude when lactate was the 
gluconeogenic substrate in comparison with fructose, these results suggest that in the 
Bauhinia megalandra leaf extract compounds are present that inhibit the gluconeogenesis at a 
point further on than the entrance of both substrates. 
The microsomal fraction used as source of the enzyme glucose-6-phosphatase was prepared 
as described elsewhere (Marcuci et al., 1983), briefly: livers from overnight fasted rat were 
homogenized in 3 volumes of 0.32 M sucrose, 3 mM MgCl2, centrifuged at 20000 g for 20 
min at 4º C, the supernatant was centrifuged at 105000 g for 1h at 4º C, the pellet constituting 
the microsomal fractions and was resuspended in 0.25 M sucrose 1 mM MgCl2 5 mM HEPES 
pH 6.5 at a final protein concentration of 20 mg/mL and kept at -80º C until use. The entire 
microsomal fraction used in this work was at least constituted by 95 % intact vesicles. 
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Fig. 4. Bauhinia megalandra, flower and leaves. 
 
Incubation  Control Bauhinia megalandra 
Time (min) Lactate or Fructose Lactate Fructose 
30 31.1 ± 9.3 15.9 ± 7.3 18.1 ± 3.8  
60 54.5 ± 17.2 11.6 ± 6.5 38.0 ± 6.0 
90 90.2 ± 18.5 16.9 ± 8.8 34.0 ± 9.0 
Table 1. Effects of Bauhinia megalandra leaf aqueous extract on hepatic gluconeogenesis. Liver 
slices from 48 hours fasted rats were incubated in Krebs-Ringer bicarbonate, supplemented 
with oleic acid saturated bovine serum albumin and in the presence of lactate or fructose as 
gluconegenic substrate in the absence (control) or in the presence of 1 mg/mL of the 
Bauhinia megalandra leaf extract. At the indicated times, samples of the medium were 
withdrawn in order to measure glucose by the glucose oxidase-peroxidase method (Trinder 
1969). The results are expressed in nmol of glucose produced/mg of liver dry weight and 
correspond to the means of 8-13 experiments ± standard deviation. The differences between 
control and plant extract treated were statistically significant at p<0.05 for fructose and 
p<0.005 for lactate. 
The activity of the enzyme glucose-6-phosphatase was carried out following the method 
described by Burchell et al., (1988) using glucose-6-phosphate or pyrophosphate as substrate in 
intact and disrupted (histone treated) hepatic microsmes. In brief, in a volume of 0.1 mL, 1-30 
mM glucose-6-phosphate, 2 mM EDTA, 16 mM HEPES, pH: 6.5 and approximately 20 μg of 
microsomal proteins were present. In order to disrupt microsomes, 80 μg of histones were 
present in the incubation medium. The reaction was carried out at 30º C for 10 min without 
shaking and stopped by the addition of 0.9 mL of 0.28 % ammonium molybdate, 1.11 % SDS 
and 1.11 % ascorbic acid in 0.33 M sulphuric acid. The colour was developed at 47º C for 20 
min and the absorbance was read at 820 nm. The assay was similar when pyrophosphate was 
www.intechopen.com
 
Phytochemicals – Bioactivities and Impact on Health 
 
338 
the substrate of the enzyme with the following differences: 0.5-5 mM pyrophosphate, 16 mM 
cacodilate, pH: 6.5, and the colour was developed at 30º C during 10 mim.  
 
 Glucose-6-phosphate as substrate 
 Intact Disrupted 
 VMAX KM VMAX KM 
Control 7.4 ± 0.9* 5.4 ± 1.1 9.8 ± 0.8 0.6 ± 0.1 
10 μg/mL 6.2 ± 1.4 5.6 ± 0.7 9.8 ± 0.7 0.7 ± 0.2 
20 μg/mL 5.1 ± 1.0* 7.5 ± 0.6 9.5 ± 0.3 0.7 ± 0.1 
 
 Pyrophosphate as substrate 
 Intact Disrupted 
 VMAX KM VMAX KM 
Control 6.6 ± 1.4 1.3 ± 0.5 7.0 ± 0.9 0.4 ± 0.1 
10 μg/mL 5.7 ± 1.6 1.0 ± 0.6 7.4 ± 0.8 0.4 ± 0.2 
20 μg/mL 6.0 ± 1.5 1.2 ± 0.4 6.6 ± 1.3 0.3 ± 0.3 
Table 2. Kinetic parameters of hepatic microsomal glucose-6-phosphatase in the absence or 
presence of the aqueous extract of Bauhinia megalandra leaves. The activity of the hepatic 
microsomal glucose-6-phosphatase was assayed using glucose-6-phosphate or 
pyrophosphate as substrate in the absence (control) or in the presence of the indicated 
concentration of the aqueous extract of Bauhinia megalandra leaves. The kinetic parameters 
were calculated from the Michaelis and Menten graphs using the Enzfitter program 
(Leatherbarrow 1987) and the VMAX for glucose-6-phosphatase activity is expressed in μmol 
of phosphate liberated/h x mg of microsomal proteins and the VMAX for the 
pyrophosphatase activity is expressed in μmol of pyrophosphate hydrolyzed/h x mg of 
microsomal proteins; for both the KM is expressed in mM. The experiments were performed 
using the liver of 3-5 fasted (24 h) rats, and each point represents the mean of 3-4 
experiments ± standard deviation. * Means differences statistically significant at p< 0.05. 
As shown in Table 2, when glucose-6-phosphate was the substrate of the glucose-6-
phosphatase of intact microsomes, the plant extract decreased in a statistically significant 
way the VMAX with a moderate increase of the KM without affecting the enzyme of disrupted 
microsomes.  
The plant extract was without effect on the glucose-6-phosphatase activity in intact or 
disrupted microsomes when pyrophosphate was the substrate (Table 2). These results 
suggest that the compounds present in the Bauhinia megalandra aqueous extract inhibit one 
of the transporters of the glucose-6-phosphatase system, probably T1 (Gonzalez-Mujica et 
al., 1998). The inhibition of the hepatic gluconeogenesis could be a consequence of the 
inhibition of the glucose-6-phosphate transporter (T1). 
The glucose-6-phosphatase activity of non-treated microsomes, when assayed with 15 mM 
glucose-6-phosphate as substrate, was linear during 30 min. (Figure 5); in the other hand, in 
the presence of 20 μg/mL of the plant extract the enzyme activity was linear just up to 20 
min, but all the values were lower than the control, after that an inflexion occurred and the 
slope of the line declined (Figure 5), suggesting that some compound(s) present in the 
Bauhinia megalandra leaf extract inhibit other transporter of the glucose-6-phosphatase 
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system, different than T1, and in consequence the enzyme products accumulated in the 
microsomal cistern leading to inhibition of the catalytic subunit. Due to the fact that the 
plant extract does not affect the kinetic parameters of the glucose-6-phosphatsase using 
pyrophosphate as substrate, there is no effect on the pyrophosphate transporter (T2), it is 
possible to suggest that the inhibition occurs at the glucose transporter (T3). 
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Fig. 5. Effects of Bauhinia megalandra leaf extract on the time course of hepatic microsomal 
glucose-6-phosphatase. The activity of the glucose-6-phosphatase was measured in the 
absence (■) or in the presence (●) of 20 μg/mL of Bauhinia megalandra leaf extract at 15 mM 
glucose-6-phosphate; each point represents the mean of 5 experiments and the vertical bars 
correspond to standard deviation. The enzyme activity is expressed in μmol of phosphate 
(Pi) released /hour x mg of protein. All the differences observed between control and extract 
treated microsomes were statistically significant at p < 0.05 except that seen at 20 min. 
3. Isolation and identification of flavonoids from Bauhinia megalandra leaves. 
Characterization of their effects on hepatic microsomal glucose-6-
phosphatase and gluconeogenesis 
We fractionated the methanol extract of fresh Bauhinia megalandra leaves using different 
solvents (methanol : water 1:1; ethyl acetate : acetone 8:2) and column chromatography on 
sephadex LH-20 and RP-18 (Estrada et al., 2005) to obtain the following flavonoids: astilbin 
(1) , quercetin 3-O-ǂ-rhamnoside (2), kaempferol 3-O-ǂ-rhamnoside (3), quercetin 3-O-ǂ-
arabinoside (4), quercetin 3-O-ǂ-(2”-galloyl)rhamnoside (5), kaempferol 3-O-ǂ-(2”-
galloyl)rhamnoside (6), quercetin (7) and kaempferol (8). The identification of the above 
mentioned flavonoids was established by comparing their 1H and 13C 
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NMR chemical shifts and proton coupling constants in DMSO-d6 with those reported 
(Agrawal, 1989; Markham and Geiger, 1994; De Brito et al., 1995; Méndez et al., 1995; Bilia et 
al., 1996) and the structure of compounds 5 and 6 is shown in Figure 6. To the best of our 
knowledge, this was the first report of the isolation of kaempferol 3-O-ǂ-(2”-
galloyl)rhamnoside from nature.  
The effect of the isolated flavonoids on the activity of the hepatic glucose-6-phosphatase was 
carried out using intact and disrupted microsomes with glucose-6-phosphate as substrate as 
indicated above. 
The inhibition of the enzyme by the flavonoids isolated from Bauhinia megalandra leaves in 
intact microsomes, but not in disrupted ones (Table 3), is a clear indication that they interact 
with the glucose-6-phosphate transporter (T1) of the glucose-6-phosphatase system with no 
effect on the catalytic subunit. It is interesting to point out that the flavonoids tested behave 
in a similar way to phlorizin (Table 3) only inhibiting the T1 transporter (Arion et al., 1980). 
 
 
Fig. 6. Structure of quercetin 3-O-ǂ-(2”-galloyl)rhamnoside (5) and kaempferol 3-O-ǂ-(2”-
galloyl)rhamnoside (6) 
As can be seen in Table 3, the aglycones, quercetin (7) and kaempferol (8), showed the 
lowest inhibitory effect on the enzyme and the percentage inhibition increased with the 
addition of the polar group rhamnose or arabinose as in the case of compounds 1, 2, 3 and 4, 
which exhibited moderate effects. The flavanonol glycoside evaluated (1) showed a similar 
behavior to compounds 2 and 3, but to a smaller extent; this could be attributed to the 
saturation of the double bond in the C-ring of the flavonoid nucleus. The strongest 
inhibitory effect was observed when the galloyl moiety was present (5 and 6). This 
observation suggests the possibility of a particular interaction between this polyphenolic 
residue and the glucose-6-phosphate transporter (T1), because the complex formation 
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between proteins and tannins in which gallic acid is usually one of the main components, is 
well known (Haslam et al., 1989). 
 
 Intact microsomes Disrupted microsomes 
Compound Activity %  IC50 Activity %  
Control 2.77 ± 0.28   5.66 ± 0.45  
Astilbin (1) 2.23 ± 0.42a -19.5 9.59 ± 27 5.80 ± 0.43 +2.5 
Quercetin 3-O-ǂ-rhamnoside (2) 1.95 ± 0.36b -29.6 246 ± 5 5.42 ± 0.53 -4.2 
Kaempferol 3-O-ǂ-rhamnoside (3) 2.04 ± 0.25b -26.4 186± 4  5.84 ± 0.46 +3.2 
Quercetin 3-O-ǂ-arabinoside (4) 2.04 ± 0.23b -26.4 1069 ± 31 5.77 ± 0.18 +3.0 
Quercetin 3-O-ǂ-(2”-
galloyl)rhamnoside (5) 
1.02 ± 0.22c -63.2 27 ± 1 6.43 ± 0.52a +13.6 
Kaempferol 3-O-ǂ-(2”-
galloyl)rhamnoside (6) 
0.93 ± 0.27c -66.4 31 ± 2 6.61 ± 0.41b +16.8 
Quercetin (7) 2.43 ± 0.05c -12.3 1330 ± 39 5.81 ± 0.52 +2.7 
Kaempferol (8) 2.71 ± 0.49 -2.2 555 ± 6 5.98 ± 0.16 +5.7 
Phorizin 2.00 ± 0.11b -27.8 4.66 ± 19 5.71 ± 0.40 +0.9 
Table 3. Effects of flavonoids isolated from Bauhinia megalandra on glucose-6-phosphatase. 
The glucose-6-phosphatase was assayed using 5 mM glucose-6-phosphate as substrate in 
intact and disrupted microsomes in the absence (control) or presence of 50 μM of each of the 
flavonoids isolated from Bauhinia megalandra leaves or 50 μM phlorizin. The enzyme activity 
is expressed as μmol of phosphate released /h x mg of microsomal protein and each value 
represents the means of 5-9 experiments ± standard deviation. The percentage inhibition (-) 
or activation (+) was also calculated. 
The IC50 was carried out following Arion et al., (1998) using intact microsomes with 1mM 
glucose-6-phosphate in the presence of increasing concentrations (including values below 
and above the IC50) of the isolated flavonoids; the result are the average of 3 experiments ± 
standard deviation, and expressed in μM.  
The increase in the glucose-6-phosphatase inhibition capacity with increase in the polarity of 
the flavonoids suggests a specific interaction with the glucose-6-phosphate transporter of 
the enzyme system because it cannot be related to a higher solubility in the endoplasmic 
reticulum membrane. Also, the interaction seems to be specific view of the fact that none of 
the flavonoids was able to inhibit the catalytic subunit of the glucose-6-phosphatase system 
(Table 3). The greater enzyme inhibition exerted by quercetin (7) in comparison to 
kaempferol (8)(Table 3) could be explained by the fact that the former has one additional 
vicinal hydroxyl group on the B-ring with respect to the latter. The difference in polarity 
between the aglycones is overcome by the presence of the carbohydrate and galloyl 
moieties, and in consequence, the inhibitory effect was also affected. 
The compounds 5 and 6 showed the lowest IC50 value and were very close to each other 
(Table 3). The lack of gallic acid in compounds 2 and 3 increased the IC50 value 9 and 6 times 
respectively, with respect to compounds 5 and 6. The aglycones, compounds 7 and 8, 
exhibited high IC50 values, which are 49 and 18 times higher than those obtained with 
compounds 5 and 6, respectively (Table 3). Compounds 1 and 4, although glycosylated, 
showed high IC50 values, comparable to that observed with the aglycone quercetin (7). To 
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our knowledge, this has been the first report of the IC50 for phlorizin and glucose-6-
phosphatase.There is a good agreement between the percentages of glucose-6-phosphatase 
inhibition and the IC50 produced by the flavonoids tested. The sugar bound to the flavonoid 
seems to be important due to the fact that substitution of rhamnose by arabinose increases 
by more than 4 times the IC50 (Table3). The reduction of the double bond of ring C, in 
astilbin, also increases the IC50 by almost 4 times (Table 3). 
All the flavonoid isolated, but one (2) produce activation of the glucose-6-phosphatase 
catalytic subunit, however, only compounds 5 and 6 (Table 3) do so to an appreciable 
magnitude and this could be due to modifications in the microsomal membranes that expose 
the active center of the enzyme, as a consequence of the presence of the tannic flavonoids. 
Due to the fact, that quercetin 3-O-ǂ-(2”-galloyl)rhamnoside (5) exerts high  inhibition of the 
T1 transporter of the glucose-6-phosphatase system and showed the lowest IC50 of all the 
flavonoids tested, we studied the effects of that compound on the kinetic parameters of the 
enzyme using glucose-6-phosphate or pyrophosphate as substrate. The enzyme assay was 
carried out as described above. The enzyme assays, with both substrates were carried out in 
the absence (control) or presence of 15 μM quercetin 3-O-ǂ-(2”-galloyl)rhamnoside (5).  
 
Glucose-6-phosphate as substrate 
 Intact microsomes Disrupted microsomes 
 VMAX KM VMAX KM 
Control 7.59 ± 0.91 4.78 ± 1.10 11.57 ± 1.55 0.79 ± 0.27 
Quercetin 3-O-ǂ-(2”-galloyl)rhamnoside (5) 7.36 ± 1.79 7.44 ± 0.42* 10.47 ± 1.45 0.57 ± 0.17 
Pyrophosphate as substrate 
 Intact microsomes Disrupted microsomes 
 VMAX KM VMAX KM 
Control 7.61 ± 2.45 2.28 ± 1.35 8.40 ± 1.73 0.40 ± 0.11 
Quercetin 3-O-ǂ-(2”-galloyl)rhamnoside (5) 6.72 ± 1.33 1.87 ± 0.41 7.58 ± 0.73 0.24 ± 0.07 
Table 4. Effects of quercetin 3-O-ǂ-(2”-galloyl)rhamnoside (5) on the kinetic parameters of 
the glucose-6-phosphatase. Microsomal glucose-6-phosphatase was assayed using glucose-
6-phosphate (1-30 mM) or pyrophosphate (0.5-5 mM) as substrate in the absence (control) or 
presence of 15 μM quercetin 3-O-ǂ-(2”-galloyl)rhamnoside (5) as described in the text. The 
kinetic parameters were calculated from the Michaelis and Menten graph using the Enzfitter 
program. The VMAX is expressed as μmol of phosphate released /h/mg proteins when 
glucose-6-phosphatase was the substrate and in μmol of pyrophosphate hydrolysed /h/mg 
proteins and the KM in mM. Each value represents the means of 3-5 experiments ± standard 
deviation and in each experiment, the livers of 3-4 rats were used. * Means differences 
statistically significant at p< 0.005.  
Table 4 show the effects of quercetin 3-O-ǂ-(2”-galloyl)rhamnoside (5) on the kinetic 
parameters of the microsomal glucose-6-phosphatase using glucose-6-phosphate or 
pyrophosphate as substrate. In controls using glucose-6-phosphate as substrate, when the 
microsomes were disrupted by the presence of histones, there was an increase in the VMAX 
with a latency of 34.4% and the KM was 1/6 of the value observed in the intact system; these 
results are in good agreement with those reported elsewhere (Blair and Burchell, 1988; 
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Gonzalez-Mujica et al., 1993, 1998). In intact microsomes the presence of quercetin 3-O-ǂ-(2”-
galloyl)rhamnoside (5) increased the KM for glucose-6-phosphate by nearly 56%, a change 
that was statistically significant at p < 0.005. On the other hand, there were no changes in the 
VMAX of intact microsomes neither in the VMAX nor in the KM of the disrupted system. When 
pyrophosphate was the substrate, the activity showed a lower latency (9.4%) and a similar 
decrease of the KM (1/6) compared with that shown when glucose-6-phosphate was the 
substrate and the microsomes were disrupted, results that are similar to those reported by 
others (Blair and Burchell, 1988; Gonzalez-Mujica et al., 1993, 1998). The kinetic parameters 
of the enzyme using pyrophosphate as substrate in intact and disrupted microsomes were 
not altered by the inclusion of the flavonol. 
From the above results: increase of the KM for glucose-6-phosphate in intact microsomes 
without affecting the other kinetic parameter in intact or disrupted microsomes using 
glucose-6-phosphate or pyrophosphate as substrates, is a clear indication that quercetin 3-O-
ǂ-(2”-galloyl)rhamnoside (5) behaves as a competitive inhibitor of the T1 transporter with 
out altering the catalytic subunit nor the other transporters of the glucose-6-phosphatase 
system. It is interesting to point out that a synthetic derivative of chlorogenic acid, a 
compound without any structural relationship with glucose-6-phosphate has been reported 
as a competitive inhibitor of T1 (Arion et al., 1998)  
Hepatic gluconeogenesis was studied using 48 h fasted rat liver slices of 200 μm thick 
incubated in Krebs-Ringer bicarbonate buffer, as described above, in the absence (control) or 
the presence of 30 μM quercetin 3-O-ǂ-(2”-galloyl)rhamnoside (5). The incubations were 
carried out with 10 mM lactate as gluconeogenic substrate, at 37 °C, under an O2:CO2 (95:5) 
atmosphere, with continuous shaking in an orbital bath (60 cycles/min), for a total time of 
90 min. Samples for glucose determination were taken every 30 min. At the end, the slices 
were dehydrated with acetone and dried at 70 °C for 24 h and the dry weight of the slices 
was determined. Glucose determination was made by the glucose oxidase method (Trinder, 
1969) and the gluconeogenic activity was expressed as nmol of glucose produced/mg liver 
dry weight. 
The gluconeogenic capacity of the rat liver slices in the absence (control) and presence of 
quercetin 3-O-ǂ-(2”-galloyl)rhamnoside (5) is shown in Fig. 7. The glucose production by the 
control liver slices was almost linear with time and similar to that reported earlier (Gonzalez-
Mujica et al., 1998). Quercetin 3-O-ǂ-(2”-galloyl)rhamnoside (5) drastically reduced the 
gluconeogenic capacity of the liver slices at all the times studied: at 30 min the inhibition was 
approximately 85%; the inhibition was nearly 50% at 60 min. and 41% at 90 min. 
The inhibition of the T1, the glucose-6-phosphate transporter, of the hepatic microsomal 
glucose-6-phosphatase system by quercetin 3-O-ǂ-(2”-galloyl)rhamnoside (5), might explain 
the inhibition of the gluconeogenic capacity of the rat liver slices in the presence of the 
flavonol and, in turn, could reduces the hepatic glucose production; this antihyperglycaemic 
effect serve to decrease the blood glucose level in diabetic patients. 
4. Effects of Bauhinia megalandra leaf aqueous extract on glycogenolysis 
An aqueous extract of Bauhinia megalandra leaves was administered by a gastric tube to rats 
anesthetized with sodium pentobarbital (30 mg/Kg body weight), 1 h later a blood sample 
was taken from the tail and 0.15 mg/Kg body weight of epinephrine (Cori and Cori 1928)  was  
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Fig. 7. Effects of quercetin 3-O-ǂ-(2”-galloyl)rhamnoside (5) on hepatic gluconeogenesis. Liver 
slices from 48 h fasted rats were incubated in 4 mL Krebs-Ringer bicarbonate buffer 
supplemented with oleate saturated albumin using lactate as gluconeogenic substrate, in the 
absence (light grey) or presence of 30 μM of Quercetin 3-O-ǂ-(2”-galloyl)rhamnoside (5) (dark 
gray). At the indicated times, medium samples were withdrawn in order to measure glucose 
by the glucose oxidase method. The results are the average of 7–9 separate experiments ± 
standard deviation. All the differences between the gluconeogenesis of controls and quercetin 
3-O-ǂ-(2”-galloyl)rhamnoside (5) treated liver slices were statistically significant at p < 0.005. 
given by intraperitoneal injection, and afterwards blood samples were taken, as before, 
every 30 min for 2 h; glucose was estimated by the glucose oxidase-peroxidase method 
(Trinder 1969).  
As shown in Figure 8, the administration of epinephrine substantially increases the 
glycaemia with a maximum at 60 min (over 80 % increases). When the plant extract was 
given before the catecholamine there was an important reduction of the hyperglycaemia 
induced by epinephrine (over 24 % reduction), been statistically significant at 60 min 
(Fernández- Peña, et al., 2008). These results suggest the intestinal absorption of compounds 
present in the Bauhinia megalandra leaves, which reach the liver via the portal vein and are 
capable of inhibiting the glycogenolysis direct or indirectly. 
In order to establish the mechanism of action of such compounds, we incubated fed rats 
liver slices in the same way as described before (Figure 7) with just buffer alone (control) or 
in the presence of epinephrine (3.3 μM) or dibutyryl cyclic AMP (10 nM) or the plant extract 
(3.44 mg/L) or the combinations of epinephrine and the vegetal extract or dibutyryl cyclic 
AMP and the plant extract. 
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Fig. 8. Effects of Bauhinia megalandra aqueous extract on the hyperglycaemia induced by 
epinephrine. Male rats were anaesthetized (sodium pentobarbital 30 mg/Kg body weight) 
before the administration by a gastric tube of water (control -■-) or 3.44 g/Kg of body 
weight of the plant extract (-▲-). One h later the animals receive by intraperitoneal injection 
0.15 mg/Kg body weight of epinephrine and the glycaemia was measured every 30 min for 
2 h. The basal glycaemia of fed rats (100 %) was 7.2 ± 0.5 mM. The values represent the 
means ± standard deviation of 5 – 6 experiments and in each 3 rats were used. At 60 min the 
differences between control and experimental was statistically significant a p < 0.001.  
As shown in Figure 9 the amount of glucose released by the rat liver slices was increased by 
the presence of the catecholamine, being 60 and 54% of the control values at 60 and 90 min 
respectively. When epinephrine and the plant extract were present simultaneously, the 
glucose production by the liver slices was almost parallel with, but significantly lower than 
that observed with the hormone alone (Figure 9), being 35; 25 and 24% of the control values 
at 30; 60 and 90 min respectively. It is interesting to point out, that at 30 min the glucose 
production in the joint presence of epinephrine and the plant extract was 35% lower than 
that observed in the control. 
As shown in Figure 10, the presence of dibutyryl cAMP produced an increase in the glucose 
release by the liver slices (Fernández-Peña, et al., 2008) at all times studied, being more 
evident at 60 min, when it was 2.6 times the control value. 
In the joint presence of the cyclic nucleotide and the plant extract there was a drastic 
reduction of the dibutyryl cAMP effect, at 60 min the glucose production was decreased by 
almost 50 %. The results presented (Figures 8; 9 and 10) strongly suggest that in Bauhinia 
megalandra leaf extract there are compounds that inhibit hepatic glycogenolysis. We also 
presented evidences that the plant extract inhibits the gluconeogenesis (Table 1 and Figure 7),  
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Fig. 9. Effects of epinephrine and of Bauhinia megalandra leaf extract on hepatic 
glycogenolysis. Fed rats liver slices were incubated in 4 mL of Krebs-Ringer bicarbonate 
buffer pH 7.4 in an atmosphere of O2/CO2 95/5 without additions for control (-■-), or in the 
presence of 3.3 μM epinephrine (-▲-), or the combination of 3.3 μM epinephrine and 13.8 μg 
of the plant extract (-☻-). At the indicated times glucose was measured in samples of the 
incubation medium as before. The values are the means ± standard deviations of 5 – 6 
experiments, in each 3 rats were used. At 60 and 90 min, the differences between 
epinephrine and control and the combination of epinephrine and the plant extract were 
statistically significant at p< 0.001. 
and due to the fact that the only enzyme common to both metabolic pathways, 
glycogenolysis and gluconeogenesis is the glucose-6-phosphatase in consequence this 
enzyme should be the target of the compounds present in Bauhinia megalandra leaf extract. 
Furthermore, the plant extract and the flavonoids isolated from it, inhibit the T1, the 
glucose-6-phosphate transporter of the hepatic microsomal glucose-6-phosphatase system. 
The above result, strongly suggest that the flavonoids present in Bauhinia megalandra leaf 
extract inhibit hepatic glycogenolysis and gluconeogenesis because of inhibition of the 
glucose-6-phosphatase and in consequence there is a reduction in the glucose production by 
the liver. These flavonoids might be useful in the treatment of non insulin dependent 
diabetes because of its antihyperglycaemic activity. 
5. Effects of Bauhinia megalandra aqueous extract and Kaempferol 3-O-α-
rhamnoside on glucose intestinal absorption 
The glucose intestinal absorption was measured by the method described by Gonzalez-
Mujica et al., (2003). In rats anaesthetized with sodium pentobarbital (60 mg/Kg body 
weight), the intestine was exposed and divided in situ into 4 cm segments by ligatures; 1 mL 
of 10 mM glucose, 0.9 % NaCl alone or with the plant extract (1.14-9.10 mg) or extract 
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Fig. 10. Effects of dibutyryl cAMP and of Bauhinia megalandra leaf extract on hepatic 
glycogenolysis. All conditions were the same as those indicated in Figure 9, without 
addition for control (-■-), or in the presence of 10 nM of dibutyryl cAMP(-▲-), or the 
combination of 10 nM of dibutyryl cAMP and 13.8 μg of the plant extract (-☻-). At 60 min 
the differences observed between the values obtained in the presence of the cyclic nucleotide 
alone and those in controls and in the presence of the mixture of dibutyryl cAMP and the 
plant extract were statistically significant at p< 0.001. 
fractions (10 mg/mL) or pure compounds (5 mM), as indicated in the figures, was injected. 
Phlorizin, a well known inhibitor of sodium-glucose cotransporter 1 (SGLT1)(Panayatova-
Heiermann, et al., 1995), at a concentration of 0.1 mM was used as a positive control. After 30 
min the intestinal segment contents were recovered without significant change in volume, 
and the glucose was measured (Trinder, 1969).  
As shown in Table 5, the aqueous extract of Bauhinia megalandra leaves inhibits the glucose 
intestinal absorption in a concentration- dependant way. When the plant extract (4.55 mg) 
was injected together with 0.1 mM phlorizin, an additive inhibitor effect was observed. The 
concentration dependent inhibition exerted by the plant extract indicates a specific action 
and due to the fact that phlorizin is a known inhibitor of the sodium-glucose cotransporter 1 
(Panayatova-Heiermann, et al., 1995), the observed additive effect of Bauhinia megalandra leaf 
extract and phlorizin suggest that in the plant there are compounds that inhibit that 
cotransporter. 
Vesicles from enterocyte apical membrane were prepared by the Ca++ precipitation method 
described by Kessler et al., (1978). The intestinal membrane vesicles obtained contained 
maltase measured as described by SaMoita, et al., (1989) in a ratio vesicles/homogenate 9.84; 
a small amount of Na+/K+ ATPase sensitive to ouabain, estimated following Del Castillo & 
Robinson (1982) in a ratio vesicles/homogenate 0.42; succinate-cytochrome c reductase  
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A B 
B megalandra 
Extract 
nmol of glucose absorbed Addition 
nmol of glucose 
absorbed 
0 mg 774.2 ± 34.4* 0 773.6 ± 70.3 
1.14 mg 602.2 ± 103.2** 
4.55 mg B megalandra extract 348.9 ± 79.1** 
2.28 mg 464.5 ± 60.2** 
4.55 mg 395.7 ± 51.6** 0.1 mM phlorizin 392.1 ± 80.9** 
6.5 mg 223.7 ± 36.1** 4.55 mg B megalandra 
extract + 0.1 mM phlorizin
87.9 ± 35.2** 
9.10 mg 141.1 ± 25.8** 
Table 5. Effects of Bauhinia megalandra extract on glucose intestinal absorption. In each of 
four consecutive intestinal segments were injected, in situ, 1mL of 10 mM glucose, 0.14% 
NaCl alone (0 mg) or in the presence of increasing amounts of Bauhinia megalandra leaf 
extract (A); or in the presence of 4.55 mg of the plant extract, or 0.1 mM phlorizin or the 
combination of 4.55 mg of plant extract and 0.1 mM phlorizin (B). After 30 min the glucose 
was measured in the intestinal segments content, expressed in nmol of glucose absorbed in 
30 min and each value corresponds to the mean ± standard deviation of eight experiments. * 
Means p< 0.005 and ** means p<0.0005. 
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Fig. 11. Effects of Bauhinia megalandra on 14C-glucose uptake by enterocyte brush border 
membrane vesicles. Rat enterocyte brush border membrane vesicles internally filled with 
100 mM KCl were incubated with 2 mM 14C-glucose (0.1 μCi) and 100 mM NaCl for the 
control (-■-) or with the addition of 4.55 μg of Bauhinia megalandra aqueous extract  (-▲-) or 
with the addition of 1 mM phlorizin (-☻-). At the indicated times the reaction was stopped 
by the fast filtration method (Hopfer, et al., 1973) and the radioactivity was measured. The 
values are expressed in nmol of glucose uptake/ mg of vesicles protein and correspond to 
the mean ± standard deviation of 9 experiments with at least 2 rats in each one. 
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quantified by the method of Green, et al., (1955) in a ratio vesicles/homogenate 0.36 and ǃ-
glucuronidase measured as described by Bergmeyer (1965) in a ratio vesicles/homogenate 
0.09. Electronmicroscopy showed vesicles with a single membrane without electron dense 
material inside. These results are in good agreement with those reported by Kessler et al., 
(1978) and indicate that the vesicles fraction obtained was enriched with brush border 
membrane, with low contamination with other cellular membrane. The 14C-glucose uptake 
by the intestinal brush border membrane vesicles, obtained as described above, was 
performed by the fast filtration method (Hopfer, et al., 1973) in the absence or presence of 
the Bauhinia megalandra leaves extract or 1mM phlorizin.  
As shown in Figure 11 the 14C-glucose uptake by intestinal brush border membrane vesicles 
exhibits a peak at 30 s followed by a plateau between 45 and 150 s, a result very similar to 
that previously published (Kessler et al., 1978). When the intestinal brush border membrane 
vesicles were incubated in the presence of 4.55 μg of the plant extract or 1 mM phlorizin 
there was complete inhibition of the 30 s 14C-glucose peak uptake. These results clearly 
indicate that in the plant extract there are compounds that inhibit the sodium-glucose 
cotransporter 1 and in consequence are similar to those reported for green tea polyphenols 
(Kobayashi, et al., 2000) and soyabean isoflavone (Vedavanam, et al., 1999).    
As shown in Figure 12-A, the simultaneous administration of Bauhinia megalanda leaf extract 
(260 mg) together with glucose (1g/Kg body weight) by gastric catheter produced an almost 
flat glucose tolerance, with a decrease in nearly 28 % in the 30 min peak which was 
statistically significant in comparison with the control receiving water instead of the plant 
extract. On the other hand, when the Bauhinia megalandra leaf extract (260 mg) was 
administrated orally and the glucose (1g/Kg body weight) by subcutaneous injection 
(Figure 12-B) there was no difference with the control that received water instead of the 
plant extract. The flat oral glucose tolerance (Figure 12-A) in comparison with the normal 
subcutaneous glucose tolerance (Figure 12-B) when the glucose was administered 
simultaneously with plant extract, strongly suggest that the main effect of Bauhinia 
megalandra extract is on the glucose intestinal absorption without any important effect on 
insulin release nor on the tissue glucose consumption. 
We tested the effects of: quercetin 3-O-ǂ-rhamnoside (2), kaempferol 3-O-ǂ-rhamnoside (3) 
and kaempferol 3-O-ǂ-(2”-galloyl)rhamnoside (6), presented in Table 3, with the intention to 
establish the compound, present in Bauhinia megalandra leaves, responsible for the inhibition 
of the glucose intestinal absorption. The glucose intestinal absorption was measured using 
the method described above (Gonzalez-Mujica, et al., 2003) in the absence (control) or the 
presence of 5 mM of the compounds 2, 3 or 6; phlorizin at a concentration of 0.1 mM was 
used as a positive control. The combined effect of kaempferol 3-O-ǂ-rhamnoside (3) and 0.1 
mM phlorizin was also studied (Rodríguez et al., 2010). The kinetic parameters, KM and 
VMAX, of glucose intestinal absorption were measured using increasing glucose 
concentration (12.5 – 50 mM), in the absence and in the presence of 5 mM kaempferol 3-O-ǂ-
rhamnoside (3), but reducing the time of absorption to 15 min in order to guarantee 
measurement at the initial velocity. KM and VMAX were calculated from the Michaelis and 
Menten graph (Rodríguez et al., 2010) using the Enzfitter program (Leatherbarrow, 1989).  
As shown in Table 6, kaempferol 3-O-ǂ-rhamnoside (3) exerts a statistically significant 
inhibition of glucose intestinal absorption, which was more than double that exhibited by 
quercetin 3-O-ǂ-rhamnoside (2), inhibition also statistically significant; on the other hand 
kaempferol 3-O-ǂ-(2”-galloyl)rhamnoside (6) lacked any effect. 
www.intechopen.com
 
Phytochemicals – Bioactivities and Impact on Health 
 
350 
                                                    
                                                    
                                                    
                                                    
                                                    
                                                    
0 30 60 90 120
80
100
120
140
160
180
B
Time (min)
C
h
a
n
g
e
 i
n
 g
ly
c
a
e
m
ia
 (
%
)
 
 
                                                    
                                                    
                                                    
                                                    
                                                    
                                                    
0 30 60 90 120
80
100
120
140
160
180
200
220
*
A
C
h
a
n
g
e
 i
n
 g
ly
c
a
e
m
ia
 (
%
)
Time (min)  
* Means difference statistically significant at p< 0.005. 
Fig. 12. Effects of Bauhinia megalandra extract on oral and subcutaneous glucose tolerance. 
Rats under light anesthesia (30mg of sodium pentobarbital/Kg of body weight) received 1 
g/Kg body weight of glucose by gastric catheter (A) or by subcutaneous injection (B) 
together with 260 mg of Bauhinia megalandra leaf extract (-☻-) or an equivalent amount of 
water (-■-) by gastric catheter. At the indicated times, blood samples were taken for glucose 
determination. The glycaemia at time zero was 75.0 ± 9.4 mg/dl. The results are expressed 
as the percentage of change in relation to zero-time value (100 %) and represent the means ± 
standard deviation of 7 experiments with at least 2 rats in each one.  
Regarding chemical structure and related biological activity, it is interesting to note that the 
presence of the galloyl group bound to the rhamnosyl moiety in kaempferol 3-O-ǂ-(2”-
galloyl)rhamnoside (6) annuls the inhibitory effect of kaempferol 3-O-ǂ-rhamnoside (3). The 
rhamnosyl moiety is present in both kaempferol 3-O-ǂ-rhamnoside (3) and quercetin 3-O-ǂ-
rhamnoside (2) but only the first compound efficiently inhibit glucose intestinal absorption, 
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indicating that the hexose is not a determinant for biological activity. The presence of an H 
(kaempferol 3-O-ǂ-rhamnoside) in stead of an OH (quercetin 3-O-ǂ-rhamnoside) in the 3’ 
position of the flavonoid B ring is a determinant for the biological activity. 
 
Compound Glucose absorption 
nmol/30 min 
% inhibition 
Control 933, 4 ± 44.3  
Quercetin 3-O-ǂ-rhamnoside (2) 822.2 ± 22.1 * 12 
kaempferol 3-O-ǂ-rhamnoside (3) 666.7 ± 4.5 ** 29 
Kaempferol 3-O-ǂ-(2”-galloyl)rhamnoside (6) 895.6 ± 17.8 NS 4 
Phlorizin 700.0 ± 71.1 ** 25 
kaempferol 3-O-ǂ-rhamnoside (3) + Phlorizin 300.0 ± 44.3 *** 68 
Table 6. Effects of flovonoids purified from Bauhinia megalandra leaves and phlorizin on the 
glucose intestinal absorption. Isolated intestinal segments were injected in situ with 1 mL of 
10 mM glucose and 0.9 % NaCl for control. In the test procedures the flavonoids: quercetin 
3-O-ǂ-rhamnoside (2), kaempferol 3-O-ǂ-rhamnoside (3) or Kaempferol 3-O-ǂ-(2”-
galloyl)rhamnoside (6)were added at a final concentration of 5 mM. The final concentration 
of phlorizin used was 0.1 mM, and the combination of 5 mM kaempferol 3-O-ǂ-rhamnoside 
(3) and 0.1 mM phlorizin was also used. After 30 min the glucose absorbed was estimated. 
The results correspond to the means ± standard deviation of 4 experiments. * Indicate p< 
0.05, **Indicate p< 0.005 ***indicate p<0.001 and NS not significant, according to the Student 
t test. 
As it can be seen in Table 6, the combined use of kaempferol 3-O-ǂ-rhamnoside (3) and 
phlorizin inhibits glucose intestinal absorption by more than double the effect of either of 
these alone, indicating an additive effect of both compounds. Due to the fact that phlorizin is 
a known inhibitor of the sodium-glucose cotransporter 1 (Panayatova-Heiermann, et al., 
1995) in consequence kaempferol 3-O-ǂ-rhamnoside (3) should be acting on the same 
transporter.  
 
 KM in mM VMAX in μmol/min 
Control 38.93 ± 4.92 * 42.33 ± 5.02 NS 
Kaempferol 3-O-ǂ-rhamnoside (3) 67.24 ± 11.12 * 50.04 ± 4.59 NS 
Table 7. Effect of kaempferol 3-O-ǂ-rhamnoside (3) on the kinetic parameters of glucose 
intestinal absorption. Isolated intestinal segments were injected in situ with 0.9 % NaCl and 
increasing concentration of glucose (12.5-50 mM) for control, and in the test procedure 5 mM 
kaempferol 3-O-ǂ-rhamnoside was added. After 15 min the glucose absorbed was estimated 
and the KM and VMAX were calculated from the Michaelis and Menten graph using the 
Enzfitter program (Leatherbarrow, 1987). The results correspond to the means ± standard 
deviation of 4 experiments. * Means p< 0.005, NS means not significant according to the 
Student t test.  
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As shown in Table 7 the control values of the kinetic parameters of glucose intestinal 
absorption are different to those reported by Ader, et al., (2001) and Li, et al., (2006), however 
it is important to point out that in these two cases the KM and VMAX correspond to the 
sodium-glucose cotransporter function and in our case the kinetic parameters correspond to 
the total process of the glucose intestinal absorption. The presence of 5 mM kaempferol 3-O-
ǂ-rhamnoside (3) increases in 1.7 times the KM without a significant change by the VMAX of 
the glucose intestinal absorption, these results strongly suggest that kaempferol 3-O-ǂ-
rhamnoside (3) behaves as a competitive inhibitor of the intestinal sodium-glucose 
cotransporter 1.  
6. Intestinal absorption of flavonoids from Bauhinia megalandra 
The compounds present in the plant extract, prior to develop any biological function, have 
to be absorbed by the intestine and pass through the blood to reach the target tissue. With 
the intention of obtaining information on the intestinal absorption of the compounds present 
the Bauhinia megalandra leaves; we studied the urine of rats that drank, during a week, the 
plant extract instead of water. The urine was treated with acid acetone, the supernatant 
dried and fractionated using different solvents and column chromatography on silica gel to 
yield a compound that was present neither in the plant extract nor in the urine of the control 
rats. The structure of the compound was established using 1H and 13C NMR as being an 
ortho-substituted benzene; however, currently we do not know the types of radicals present 
(results not published). Due to the fact, that the ortho-substituted benzene was present 
neither in the plant extract nor in the Bauhinia megalandra leaf extract, this  must correspond 
to a compound, probably a flavonoid, present in the plant extract that was absorbed at the 
intestine level, afterwards metabolized and excreted in the urine. This ortho-substituted 
benzene, is different to the phenolic acid that has been reported (Touriño, et al., 2009) are 
eliminated by the urine of animals that ingest flavonoids. This is direct evidence of the 
intestinal absorption of compounds present in the Bauhinia megalandra leaf extract.  
7. Conclusions 
The aqueous extract of Bauhinia megalandra leaves inhibited the gluconeogenesis and 
glycogenolysis, stimulated by epinephrine or dibutyril AMPc, activity of liver slices, 
reduced the hyperglycaemia promoted by epinephrine in the intact animal and inhibited the 
glucose intestinal absorption in a dose dependant way by affecting the SGLT 1. From the 
methanol extract of the Bauhinia megalandra leaves, we purified and characterized 8 
flavonoids for one of which, kaempferol 3-O-ǂ-(2”galloyl)-rhamnoside (6), to the best of our 
knowledge, this was the first report of its being isolated from nature; all of the flavonoids 
isolated were able to inhibit the enzyme glucose-6-phosphatase, the most active ones being 
those with the galloyl group with IC50 of approximately 30 μM. Quercetin 3-O-ǂ-
(2”galloyl)-rhamnoside (5) behaved as a competitive inhibitor of the glucose-6-phosphatase 
transporter of the glucose-6-phosphate system and drastically reduced the liver 
gluconeogenic activity. The reduction of the glycogenolysis and gluconeogenesis might be a 
consequence of the inhibition of the hepatic glucose-6-phosphatase by the flavonoids 
present in the plant extract. Kaempferol 3-O-ǂ-rhamnoside (3) was a competitive inhibitor of 
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the glucose intestinal absorption. In the urine of the rats that drank the Bauhinia megalandra 
leaves aqueous extract we identified an ortho-substituted benzene, probably a product of 
the metabolism of one of the flavonoides. 
We have presented direct and indirect evidences of the intestinal absorption of compounds 
present in the Bauhinia megalandra leaf extract which are responsible for the reduction in the 
hepatic production of glucose and of the glucose intestinal absorption, events that are 
important for the reduction of the supply of glucose to the blood. As a  consequence the 
compounds present in this plant may well be useful in the treatment of diabetic patients due 
to their antihyperglycaemic activity.  
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